Stage I-III non-metastatic breast cancer patients with a low expression of CD82 (such as those shown in Figure 3 below) can be first identified from patient biopsies, or potentially, exosomes from the bloodstream, which is an example of a liquid biopsy using a non-invasive approach [71]. This evidence concerns the gene CD82 and breast carcinoma.